- Home
- GMED vs ROIV Comparison
GMED vs ROIV Comparison
Compare GMED & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMED
- ROIV
- Stock Information
- Founded
- GMED 2003
- ROIV 2014
- Country
- GMED United States
- ROIV United Kingdom
- Employees
- GMED N/A
- ROIV N/A
- Industry
- GMED Medical/Dental Instruments
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- GMED Health Care
- ROIV Health Care
- Exchange
- GMED Nasdaq
- ROIV Nasdaq
- Market Cap
- GMED N/A
- ROIV 8.4B
- IPO Year
- GMED 2012
- ROIV N/A
- Fundamental
- Price
- GMED $71.01
- ROIV $10.15
- Analyst Decision
- GMED Buy
- ROIV Buy
- Analyst Count
- GMED 13
- ROIV 4
- Target Price
- GMED $96.91
- ROIV $17.50
- AVG Volume (30 Days)
- GMED 1.3M
- ROIV 8.0M
- Earning Date
- GMED 05-08-2025
- ROIV 05-29-2025
- Dividend Yield
- GMED N/A
- ROIV N/A
- EPS Growth
- GMED N/A
- ROIV N/A
- EPS
- GMED 0.75
- ROIV N/A
- Revenue
- GMED $2,519,355,000.00
- ROIV $122,585,000.00
- Revenue This Year
- GMED $8.52
- ROIV N/A
- Revenue Next Year
- GMED $6.73
- ROIV N/A
- P/E Ratio
- GMED $94.68
- ROIV N/A
- Revenue Growth
- GMED 60.62
- ROIV 140.04
- 52 Week Low
- GMED $49.33
- ROIV $8.73
- 52 Week High
- GMED $94.93
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- GMED 43.99
- ROIV 50.07
- Support Level
- GMED $70.34
- ROIV $9.90
- Resistance Level
- GMED $74.34
- ROIV $10.26
- Average True Range (ATR)
- GMED 3.39
- ROIV 0.47
- MACD
- GMED 0.25
- ROIV 0.06
- Stochastic Oscillator
- GMED 53.31
- ROIV 92.81
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.